CPLX2 is a novel tumor suppressor and improves the prognosis in glioma
Background Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were...
Saved in:
| Published in | Journal of neuro-oncology Vol. 167; no. 1; pp. 63 - 74 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.03.2024
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0167-594X 1573-7373 1573-7373 |
| DOI | 10.1007/s11060-023-04548-4 |
Cover
Loading…
| Abstract | Background
Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were the focus of this investigation.
Methods
The glioma transcriptome profile was downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases for analysis of CPLX2 expression in glioma. RT-qPCR was performed to detect the expression of CPLX2 in 68 glioma subjects who have been followed up. Kaplan-Meier survival analyses were conducted to assess the effect of CPLX2 on the prognosis of glioma patients. The knockdown and overexpressed cell lines of CPLX2 were constructed to investigate the impact of CPLX2 on glioma. The cell growth, colony formation, and tumor formation in xenograft were performed.
Results
The expression of CPLX2 was downregulated in glioma and was negatively correlated with the grade of glioma. The higher expression of CPLX2 predicted a longer survival, as indicated by the analysis of Kaplan-Meier survival curves. Overexpressed CPLX2 impaired tumorigenesis in glioma progression both in vivo and in vitro. Knocking down CPLX2 promoted the proliferation of glioma cells. The analysis of GSEA and co-expression analysis revealed that CPLX2 may affect the malignancy of glioma by regulating the hypoxia and inflammation pathways.
Conclusions
Our data indicated that CPLX2 functions as a tumor suppressor and could be used as a potential prognostic marker in glioma. |
|---|---|
| AbstractList | BackgroundGlioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were the focus of this investigation.MethodsThe glioma transcriptome profile was downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases for analysis of CPLX2 expression in glioma. RT-qPCR was performed to detect the expression of CPLX2 in 68 glioma subjects who have been followed up. Kaplan-Meier survival analyses were conducted to assess the effect of CPLX2 on the prognosis of glioma patients. The knockdown and overexpressed cell lines of CPLX2 were constructed to investigate the impact of CPLX2 on glioma. The cell growth, colony formation, and tumor formation in xenograft were performed.ResultsThe expression of CPLX2 was downregulated in glioma and was negatively correlated with the grade of glioma. The higher expression of CPLX2 predicted a longer survival, as indicated by the analysis of Kaplan-Meier survival curves. Overexpressed CPLX2 impaired tumorigenesis in glioma progression both in vivo and in vitro. Knocking down CPLX2 promoted the proliferation of glioma cells. The analysis of GSEA and co-expression analysis revealed that CPLX2 may affect the malignancy of glioma by regulating the hypoxia and inflammation pathways.ConclusionsOur data indicated that CPLX2 functions as a tumor suppressor and could be used as a potential prognostic marker in glioma. Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were the focus of this investigation. The glioma transcriptome profile was downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases for analysis of CPLX2 expression in glioma. RT-qPCR was performed to detect the expression of CPLX2 in 68 glioma subjects who have been followed up. Kaplan-Meier survival analyses were conducted to assess the effect of CPLX2 on the prognosis of glioma patients. The knockdown and overexpressed cell lines of CPLX2 were constructed to investigate the impact of CPLX2 on glioma. The cell growth, colony formation, and tumor formation in xenograft were performed. The expression of CPLX2 was downregulated in glioma and was negatively correlated with the grade of glioma. The higher expression of CPLX2 predicted a longer survival, as indicated by the analysis of Kaplan-Meier survival curves. Overexpressed CPLX2 impaired tumorigenesis in glioma progression both in vivo and in vitro. Knocking down CPLX2 promoted the proliferation of glioma cells. The analysis of GSEA and co-expression analysis revealed that CPLX2 may affect the malignancy of glioma by regulating the hypoxia and inflammation pathways. Our data indicated that CPLX2 functions as a tumor suppressor and could be used as a potential prognostic marker in glioma. Background Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were the focus of this investigation. Methods The glioma transcriptome profile was downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases for analysis of CPLX2 expression in glioma. RT-qPCR was performed to detect the expression of CPLX2 in 68 glioma subjects who have been followed up. Kaplan-Meier survival analyses were conducted to assess the effect of CPLX2 on the prognosis of glioma patients. The knockdown and overexpressed cell lines of CPLX2 were constructed to investigate the impact of CPLX2 on glioma. The cell growth, colony formation, and tumor formation in xenograft were performed. Results The expression of CPLX2 was downregulated in glioma and was negatively correlated with the grade of glioma. The higher expression of CPLX2 predicted a longer survival, as indicated by the analysis of Kaplan-Meier survival curves. Overexpressed CPLX2 impaired tumorigenesis in glioma progression both in vivo and in vitro. Knocking down CPLX2 promoted the proliferation of glioma cells. The analysis of GSEA and co-expression analysis revealed that CPLX2 may affect the malignancy of glioma by regulating the hypoxia and inflammation pathways. Conclusions Our data indicated that CPLX2 functions as a tumor suppressor and could be used as a potential prognostic marker in glioma. Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were the focus of this investigation.BACKGROUNDGlioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were the focus of this investigation.The glioma transcriptome profile was downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases for analysis of CPLX2 expression in glioma. RT-qPCR was performed to detect the expression of CPLX2 in 68 glioma subjects who have been followed up. Kaplan-Meier survival analyses were conducted to assess the effect of CPLX2 on the prognosis of glioma patients. The knockdown and overexpressed cell lines of CPLX2 were constructed to investigate the impact of CPLX2 on glioma. The cell growth, colony formation, and tumor formation in xenograft were performed.METHODSThe glioma transcriptome profile was downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases for analysis of CPLX2 expression in glioma. RT-qPCR was performed to detect the expression of CPLX2 in 68 glioma subjects who have been followed up. Kaplan-Meier survival analyses were conducted to assess the effect of CPLX2 on the prognosis of glioma patients. The knockdown and overexpressed cell lines of CPLX2 were constructed to investigate the impact of CPLX2 on glioma. The cell growth, colony formation, and tumor formation in xenograft were performed.The expression of CPLX2 was downregulated in glioma and was negatively correlated with the grade of glioma. The higher expression of CPLX2 predicted a longer survival, as indicated by the analysis of Kaplan-Meier survival curves. Overexpressed CPLX2 impaired tumorigenesis in glioma progression both in vivo and in vitro. Knocking down CPLX2 promoted the proliferation of glioma cells. The analysis of GSEA and co-expression analysis revealed that CPLX2 may affect the malignancy of glioma by regulating the hypoxia and inflammation pathways.RESULTSThe expression of CPLX2 was downregulated in glioma and was negatively correlated with the grade of glioma. The higher expression of CPLX2 predicted a longer survival, as indicated by the analysis of Kaplan-Meier survival curves. Overexpressed CPLX2 impaired tumorigenesis in glioma progression both in vivo and in vitro. Knocking down CPLX2 promoted the proliferation of glioma cells. The analysis of GSEA and co-expression analysis revealed that CPLX2 may affect the malignancy of glioma by regulating the hypoxia and inflammation pathways.Our data indicated that CPLX2 functions as a tumor suppressor and could be used as a potential prognostic marker in glioma.CONCLUSIONSOur data indicated that CPLX2 functions as a tumor suppressor and could be used as a potential prognostic marker in glioma. |
| Author | Yan, Bokang Wang, Zuli Wen, Lingzhi Zhou, Xiaokun Xia, Xuewei Chen, Yuanbing Tao, Yongguang Ning, Jieling Hu, Junhong Huang, Jun Shu, Long |
| Author_xml | – sequence: 1 givenname: Yuanbing surname: Chen fullname: Chen, Yuanbing organization: Department of Neurosurgery, Third Xiangya Hospital, Central South University – sequence: 2 givenname: Jieling surname: Ning fullname: Ning, Jieling organization: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Department of Dermatology, Xiangya Hospital, Central South University – sequence: 3 givenname: Long surname: Shu fullname: Shu, Long organization: Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, NHC Key Laboratory of Carcinogenesis (Central South University), Cancer Research Institute and School of Basic Medicine, Central South University – sequence: 4 givenname: Lingzhi surname: Wen fullname: Wen, Lingzhi organization: Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, NHC Key Laboratory of Carcinogenesis (Central South University), Cancer Research Institute and School of Basic Medicine, Central South University – sequence: 5 givenname: Bokang surname: Yan fullname: Yan, Bokang organization: Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, NHC Key Laboratory of Carcinogenesis (Central South University), Cancer Research Institute and School of Basic Medicine, Central South University – sequence: 6 givenname: Zuli surname: Wang fullname: Wang, Zuli organization: Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, NHC Key Laboratory of Carcinogenesis (Central South University), Cancer Research Institute and School of Basic Medicine, Central South University – sequence: 7 givenname: Junhong surname: Hu fullname: Hu, Junhong organization: Department of Neurosurgery, Affiliated Hospital of Guilin Medical University – sequence: 8 givenname: Xiaokun surname: Zhou fullname: Zhou, Xiaokun organization: Department of Neurosurgery, Affiliated Hospital of Guilin Medical University – sequence: 9 givenname: Yongguang surname: Tao fullname: Tao, Yongguang organization: Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, NHC Key Laboratory of Carcinogenesis (Central South University), Cancer Research Institute and School of Basic Medicine, Central South University – sequence: 10 givenname: Xuewei surname: Xia fullname: Xia, Xuewei email: xxw7456@163.com organization: Department of Neurosurgery, Affiliated Hospital of Guilin Medical University – sequence: 11 givenname: Jun surname: Huang fullname: Huang, Jun email: Xyyyhj@csu.edu.cn organization: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Department of Neurosurgery, Xiangya Hospital, Central South University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38427133$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtLxDAUhYMozkP_gAsJuHETzTudpQyOCgO6UJhdSDvJ2KFNa9IK_nszdlRw4SoH7neSe3Im4NA33gJwRvAVwVhdR0KwxAhThjAXPEP8AIyJUAwpptghGGMiFRIzvhqBSYxbjDFXjByDEcs4VYSxMVjMn5YrCssIDfTNu61g19dNgLFv22BjTNL4NSzrNqRphN2rhUlufBOTp_RwU5VNbU7AkTNVtKf7cwpeFrfP83u0fLx7mN8sUcGo7JCjTlrBKXFOSu4yuVO5cYKIIkUxhZsRLrmyRDibO5phlhe7qU3rqnXOpuByuDft8Nbb2Om6jIWtKuNt00dNZywl4zjln4KLP-i26YNP22mGCZsRQalM1Pme6vParnUbytqED_39QwmgA1CEJsZg3Q9CsN7VoIcadKpBf9WgeTKxwRQT7Dc2_L79j-sTx0-IKw |
| Cites_doi | 10.1158/0008-5472.CAN-17-3454 10.1093/hmg/ddq252 10.1038/onc.2015.53 10.1038/ncpneuro0289 10.1038/s41380-017-0011-3 10.1007/s00401-016-1545-1 10.1007/s10072-015-2419-3 10.1016/j.cellsig.2018.10.020 10.1186/s12935-022-02636-5 10.2220/biomedres.38.19 10.1002/iid3.276 10.1016/j.bcp.2018.04.009 10.1093/neuonc/noz150 10.3322/caac.21613 10.1007/s00406-014-0550-4 10.1016/j.yexmp.2012.03.004 10.1016/j.brainres.2015.11.041 10.1111/j.1460-9568.2005.04349.x 10.1007/s12035-016-0156-0 10.1002/ijc.26335 10.1111/j.1601-183X.2010.00590.x 10.1007/s13311-017-0519-x 10.1093/neuonc/nox081 10.3934/mbe.2020217 10.1007/s13402-022-00734-0 10.3389/fimmu.2020.01955 10.1007/s11912-020-01006-6 10.1007/s13402-021-00629-6 10.3233/CBM-130336 10.1016/j.cell.2006.08.030 10.1016/j.febslet.2007.02.066 10.1038/s41419-018-0542-9 10.1056/NEJMra0910283 10.1007/s13402-021-00625-w 10.1093/carcin/bgs171 10.1111/nyas.14249 10.1186/s12935-021-02040-5 10.1016/j.yexmp.2022.104754 10.3390/biomedicines8070191 10.1242/bio.038851 10.15586/codon.glioblastoma.2017.ch16 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| DBID | AAYXX CITATION NPM 3V. 7TK 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s11060-023-04548-4 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Neurosciences Abstracts Proquest Health & Medical Complete ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1573-7373 |
| EndPage | 74 |
| ExternalDocumentID | 38427133 10_1007_s11060_023_04548_4 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Guangxi Zhuang Autonomous Region Health and Family Planning Commission grantid: Z20200664(X. Zhou) funderid: http://dx.doi.org/10.13039/501100011828 – fundername: National Natural Science Foundation of China grantid: 81860449(X.Xia); 81860449(X.Xia); 82160554 (J. Huang) funderid: http://dx.doi.org/10.13039/501100001809 – fundername: Natural Science Foundation of Hunan Province grantid: 2020JJ8051 (J. Huang) funderid: http://dx.doi.org/10.13039/501100004735 – fundername: Guangxi Zhuang Autonomous Region Health and Family Planning Commission grantid: Z20200664(X. Zhou) – fundername: National Natural Science Foundation of China grantid: 82160554 (J. Huang) – fundername: National Natural Science Foundation of China grantid: 81860449(X.Xia) – fundername: Natural Science Foundation of Hunan Province grantid: 2020JJ8051 (J. Huang) |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29L 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Y I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAK LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI RNS ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT NPM 7TK 7XB 8FK ABRTQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c326t-f2f6e5421ff664f8621ffbaf515c060acf914647e15febf2803bcf515e2717db3 |
| IEDL.DBID | U2A |
| ISSN | 0167-594X 1573-7373 |
| IngestDate | Fri Jul 11 12:28:49 EDT 2025 Sat Aug 16 21:43:10 EDT 2025 Wed Feb 19 02:08:17 EST 2025 Tue Jul 01 02:14:18 EDT 2025 Fri Feb 21 02:44:22 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Hypoxia Inflammation Glioma CPLX2 Tumor suppressor gene |
| Language | English |
| License | 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c326t-f2f6e5421ff664f8621ffbaf515c060acf914647e15febf2803bcf515e2717db3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 38427133 |
| PQID | 3013915226 |
| PQPubID | 37423 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2934274037 proquest_journals_3013915226 pubmed_primary_38427133 crossref_primary_10_1007_s11060_023_04548_4 springer_journals_10_1007_s11060_023_04548_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20240300 2024-03-00 2024-Mar-01 20240301 |
| PublicationDateYYYYMMDD | 2024-03-01 |
| PublicationDate_xml | – month: 3 year: 2024 text: 20240300 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Journal of neuro-oncology |
| PublicationTitleAbbrev | J Neurooncol |
| PublicationTitleAlternate | J Neurooncol |
| PublicationYear | 2024 |
| Publisher | Springer US Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer Nature B.V |
| References | Mao, Wang, Liu, Wang, Yan, Jiang, Shi, Shen, Liu, Lai (CR18) 2018; 78 Melia (CR7) 2007; 581 Shi, Tao, Jiang, Xu, Yan, Chen, Xiao, Cao (CR16) 2012; 33 Dono, Ballester, Primdahl, Esquenazi, Bhatia (CR21) 2021; 23 Chen, Zhao, Miao, Liu, Yang, Liu, Yang, Song (CR28) 2020; 11 Malfettone, Silvestris, Paradiso, Mattioli, Simone, Mangia (CR37) 2012; 92 Makuuchi, Terashima, Kusuhara, Nakajima, Serizawa, Hatakeyama, Ohshima, Urakami, Yamaguchi (CR20) 2017; 38 Mahata, Corti (CR27) 2019; 1455 Glynn, Gibson, Harte, Reim, Jones, Reynolds, Morton (CR23) 2010; 19 CR15 Varghese, Patel, Yadav (CR29) 2019; 53 CR36 Biswal, Das, Barhwal, Kumar, Nag, Thakur, Hota, Kumar (CR35) 2017; 54 Tan, Ashley, López, Malinzak, Friedman, Khasraw (CR6) 2020; 70 Chen, Smith-Cohn, Cohen, Colman (CR22) 2017; 14 Wu, Mao, Chen, Zhang, Zhang, Wu, Li (CR39) 2021; 44 Sant, Minicozzi, Lagorio, Børge Johannesen, Marcos-Gragera, Francisci (CR5) 2012; 131 Mu, Yu, Li, Wang, Cui, Zhang, Song, Liu (CR40) 2021; 44 Pan, Oliveira, Saher, Dere, Tapken, Mitjans, Seidel, Wesolowski, Wakhloo, Klein-Schmidt (CR25) 2019; 24 Jiang, Yan, Lai, Shi, Xiao, Jia, Liu, Li, Lu, Li (CR17) 2015; 34 Louis, Perry, Reifenberger, von Deimling, Figarella-Branger, Cavenee, Ohgaki, Wiestler, Kleihues, Ellison (CR3) 2016; 131 Wei, Wang, Wang, Du (CR11) 2020; 17 Eissa, Hussein, Hendy, Bernstein, Ghia (CR26) 2018; 152 CR2 Komatsu, Kakehashi, Nishiyama, Izumi, Mizuguchi, Yamano, Inoue, Hanada, Chung, Wei (CR9) 2013; 13 Masuda, Kato, Ishibashi, Nishibata, Sugimoto, Nakazawa, Tanaka, Tomaru, Tsujino, Ishizu (CR42) 2022; 125 Gu, Ren, Zheng, Hu, Hu (CR10) 2019; 20 Hass, Walton, Kirsten, Turner, Wolthusen, Roessner, Sponheim, Holt, Gollub, Calhoun (CR12) 2015; 265 Wei, Li, He, Zhang, Sun, Xu (CR34) 2016; 1631 Durrani, Bhatti, John (CR33) 2021; 21 Tang, Maximov, Shin, Dai, Rizo, Südhof (CR8) 2006; 126 Radyushkin, El-Kordi, Boretius, Castaneda, Ronnenberg, Reim, Bickeböller, Frahm, Brose, Ehrenreich (CR13) 2010; 9 Yan, Liu, Shi, Liu, Chen, Wang, Xiao, Liu, Mao, Jiang (CR19) 2018; 9 Tsuru, Oryu, Sawada, Nishihara, Tsuda (CR24) 2019; 7 Eltzschig, Carmeliet (CR41) 2011; 364 Uğurel, Şehitoğlu, Tüzün, Kürtüncü, Çoban, Vural (CR30) 2016; 37 Gibson, Reim, Brose, Morton, Jones (CR14) 2005; 22 Frontinan-Rubio, Llanos-Gonzalez, Garcia-Carpintero, Peinado, Ballesteros-Yanez, Rayo, de la Fuente, Perez-Garcia, Perez-Romasanta, Malumbres (CR31) 2023; 46 Ostrom, Cioffi, Gittleman, Patil, Waite, Kruchko, Barnholtz-Sloan (CR4) 2019; 21 Schwartzbaum, Fisher, Aldape, Wrensch (CR1) 2006; 2 Chen, Tang, Xiong, Gao, Cao, Huang (CR38) 2022; 22 Zhu, Kros, Cheng, Mustafa (CR32) 2017; 19 A Dono (4548_CR21) 2021; 23 X Chen (4548_CR28) 2020; 11 E Tsuru (4548_CR24) 2019; 7 K Wu (4548_CR39) 2021; 44 S Masuda (4548_CR42) 2022; 125 QT Ostrom (4548_CR4) 2019; 21 C Mao (4548_CR18) 2018; 78 C Zhu (4548_CR32) 2017; 19 4548_CR2 AC Tan (4548_CR6) 2020; 70 A Malfettone (4548_CR37) 2012; 92 J Hass (4548_CR12) 2015; 265 IA Durrani (4548_CR33) 2021; 21 M Sant (4548_CR5) 2012; 131 H Komatsu (4548_CR9) 2013; 13 R Chen (4548_CR22) 2017; 14 Y Jiang (4548_CR17) 2015; 34 E Uğurel (4548_CR30) 2016; 37 N Eissa (4548_CR26) 2018; 152 HE Gibson (4548_CR14) 2005; 22 Y Chen (4548_CR38) 2022; 22 HK Eltzschig (4548_CR41) 2011; 364 SK Mahata (4548_CR27) 2019; 1455 H Mu (4548_CR40) 2021; 44 B Wei (4548_CR11) 2020; 17 S Biswal (4548_CR35) 2017; 54 W Gu (4548_CR10) 2019; 20 K Radyushkin (4548_CR13) 2010; 9 Y Shi (4548_CR16) 2012; 33 B Yan (4548_CR19) 2018; 9 JA Schwartzbaum (4548_CR1) 2006; 2 B Wei (4548_CR34) 2016; 1631 J Frontinan-Rubio (4548_CR31) 2023; 46 TJ Melia Jr (4548_CR7) 2007; 581 D Glynn (4548_CR23) 2010; 19 H Pan (4548_CR25) 2019; 24 R Makuuchi (4548_CR20) 2017; 38 JF Varghese (4548_CR29) 2019; 53 DN Louis (4548_CR3) 2016; 131 J Tang (4548_CR8) 2006; 126 4548_CR36 4548_CR15 |
| References_xml | – volume: 78 start-page: 3484 issue: 13 year: 2018 end-page: 3496 ident: CR18 article-title: A G3BP1-Interacting lncRNA promotes ferroptosis and apoptosis in Cancer via Nuclear sequestration of p53 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-17-3454 – volume: 19 start-page: 3402 issue: 17 year: 2010 end-page: 3412 ident: CR23 article-title: Clorgyline-mediated reversal of neurological deficits in a complexin 2 knockout mouse publication-title: Hum Mol Genet doi: 10.1093/hmg/ddq252 – volume: 34 start-page: 6079 issue: 50 year: 2015 end-page: 6091 ident: CR17 article-title: Repression of hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8 publication-title: Oncogene doi: 10.1038/onc.2015.53 – volume: 2 start-page: 494 issue: 9 year: 2006 end-page: 503 ident: CR1 article-title: Epidemiology and molecular pathology of glioma publication-title: Nat Clin Pract Neurol doi: 10.1038/ncpneuro0289 – ident: CR2 – volume: 24 start-page: 1489 issue: 10 year: 2019 end-page: 1501 ident: CR25 article-title: Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric Disease in a novel autoimmune model publication-title: Mol Psychiatry doi: 10.1038/s41380-017-0011-3 – volume: 131 start-page: 803 issue: 6 year: 2016 end-page: 820 ident: CR3 article-title: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary publication-title: Acta Neuropathol doi: 10.1007/s00401-016-1545-1 – volume: 37 start-page: 411 issue: 3 year: 2016 end-page: 416 ident: CR30 article-title: Increased complexin-1 and decreased miR-185 expression levels in Behçet’s Disease with and without neurological involvement publication-title: Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol doi: 10.1007/s10072-015-2419-3 – volume: 53 start-page: 316 year: 2019 end-page: 326 ident: CR29 article-title: Sterol regulatory element binding protein (SREBP) -1 mediates oxidized low-density lipoprotein (oxLDL) induced macrophage foam cell formation through NLRP3 inflammasome activation publication-title: Cell Signal doi: 10.1016/j.cellsig.2018.10.020 – volume: 22 start-page: 223 issue: 1 year: 2022 ident: CR38 article-title: GRB10 is a novel oncogene associated with cell proliferation and prognosis in glioma publication-title: Cancer Cell Int doi: 10.1186/s12935-022-02636-5 – volume: 38 start-page: 19 issue: 1 year: 2017 end-page: 27 ident: CR20 article-title: Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach publication-title: Biomed Res (Tokyo Japan) doi: 10.2220/biomedres.38.19 – volume: 7 start-page: 318 issue: 4 year: 2019 end-page: 325 ident: CR24 article-title: Complexin 2 regulates secretion of immunoglobulin in antibody-secreting cells publication-title: Immun Inflamm Dis doi: 10.1002/iid3.276 – volume: 152 start-page: 315 year: 2018 end-page: 326 ident: CR26 article-title: Chromogranin-A and its derived peptides and their pharmacological effects during intestinal inflammation publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2018.04.009 – volume: 21 start-page: v1 issue: Suppl 5 year: 2019 end-page: v100 ident: CR4 article-title: CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2012–2016 publication-title: Neuro Oncol doi: 10.1093/neuonc/noz150 – volume: 70 start-page: 299 issue: 4 year: 2020 end-page: 312 ident: CR6 article-title: Management of glioblastoma: state of the art and future directions publication-title: Cancer J Clin doi: 10.3322/caac.21613 – volume: 265 start-page: 137 issue: 2 year: 2015 end-page: 145 ident: CR12 article-title: Complexin2 modulates working memory-related neural activity in patients with schizophrenia publication-title: Eur Arch Psychiatry Clin NeuroSci doi: 10.1007/s00406-014-0550-4 – volume: 92 start-page: 296 issue: 3 year: 2012 end-page: 303 ident: CR37 article-title: Overexpression of nuclear NHERF1 in advanced Colorectal cancer: association with hypoxic microenvironment and Tumor invasive phenotype publication-title: Exp Mol Pathol doi: 10.1016/j.yexmp.2012.03.004 – volume: 1631 start-page: 157 year: 2016 end-page: 164 ident: CR34 article-title: Hippocampal NMDAR-Wnt-catenin signaling disrupted with cognitive deficits in adolescent offspring exposed to prenatal hypoxia publication-title: Brain Res doi: 10.1016/j.brainres.2015.11.041 – volume: 22 start-page: 1701 issue: 7 year: 2005 end-page: 1712 ident: CR14 article-title: A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington’s Disease and in the complexin II knockout mouse publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.2005.04349.x – volume: 54 start-page: 6133 issue: 8 year: 2017 end-page: 6147 ident: CR35 article-title: Epigenetic regulation of SNAP25 prevents Progressive Glutamate Excitotoxicty in hypoxic CA3 neurons publication-title: Mol Neurobiol doi: 10.1007/s12035-016-0156-0 – volume: 131 start-page: 173 issue: 1 year: 2012 end-page: 185 ident: CR5 article-title: Survival of European patients with central nervous system tumors publication-title: Int J Cancer doi: 10.1002/ijc.26335 – volume: 9 start-page: 592 issue: 6 year: 2010 end-page: 602 ident: CR13 article-title: Complexin2 null mutation requires a ‘second hit’ for induction of phenotypic changes relevant to schizophrenia publication-title: Genes Brain Behav doi: 10.1111/j.1601-183X.2010.00590.x – volume: 14 start-page: 284 issue: 2 year: 2017 end-page: 297 ident: CR22 article-title: Glioma subclassifications and their clinical significance publication-title: Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics doi: 10.1007/s13311-017-0519-x – volume: 19 start-page: 1435 issue: 11 year: 2017 end-page: 1446 ident: CR32 article-title: The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies publication-title: Neuro Oncol doi: 10.1093/neuonc/nox081 – volume: 17 start-page: 3909 issue: 4 year: 2020 end-page: 3924 ident: CR11 article-title: Prognostic factor identification by analysis of the gene expression and DNA methylation data in glioma publication-title: Math Biosci Engineering: MBE doi: 10.3934/mbe.2020217 – volume: 46 start-page: 65 issue: 1 year: 2023 end-page: 77 ident: CR31 article-title: CoQ(10) reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation publication-title: Cell Oncol (Dordr) doi: 10.1007/s13402-022-00734-0 – volume: 11 start-page: 1955 year: 2020 ident: CR28 article-title: Inhibition of Bcl2L12 attenuates Eosinophilia-related inflammation in the heart publication-title: Front Immunol doi: 10.3389/fimmu.2020.01955 – volume: 23 start-page: 20 issue: 2 year: 2021 ident: CR21 article-title: IDH-Mutant Low-grade glioma: advances in molecular diagnosis, management, and future directions publication-title: Curr Oncol Rep doi: 10.1007/s11912-020-01006-6 – volume: 44 start-page: 1167 issue: 5 year: 2021 end-page: 1181 ident: CR39 article-title: Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1alpha/Mff regulation in head and neck squamous cell carcinoma publication-title: Cell Oncol (Dordr) doi: 10.1007/s13402-021-00629-6 – volume: 13 start-page: 171 issue: 3 year: 2013 end-page: 180 ident: CR9 article-title: Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumors publication-title: Cancer Biomark doi: 10.3233/CBM-130336 – volume: 126 start-page: 1175 issue: 6 year: 2006 end-page: 1187 ident: CR8 article-title: A complexin/synaptotagmin 1 switch controls fast synaptic vesicle exocytosis publication-title: Cell doi: 10.1016/j.cell.2006.08.030 – volume: 581 start-page: 2131 issue: 11 year: 2007 end-page: 2139 ident: CR7 article-title: Putting the clamps on membrane fusion: how complexin sets the stage for calcium-mediated exocytosis publication-title: FEBS Lett doi: 10.1016/j.febslet.2007.02.066 – ident: CR15 – volume: 9 start-page: 490 issue: 5 year: 2018 ident: CR19 article-title: Activation of AhR with nuclear IKKα regulates cancer stem-like properties in the occurrence of radioresistance publication-title: Cell Death Dis doi: 10.1038/s41419-018-0542-9 – volume: 364 start-page: 656 issue: 7 year: 2011 end-page: 665 ident: CR41 article-title: Hypoxia and inflammation publication-title: N Engl J Med doi: 10.1056/NEJMra0910283 – volume: 44 start-page: 1151 issue: 5 year: 2021 end-page: 1166 ident: CR40 article-title: Mild chronic hypoxia-induced HIF-2alpha interacts with c-MYC through competition with HIF-1alpha to induce hepatocellular carcinoma cell proliferation publication-title: Cell Oncol (Dordr) doi: 10.1007/s13402-021-00625-w – volume: 33 start-page: 1468 issue: 8 year: 2012 end-page: 1478 ident: CR16 article-title: Nuclear epidermal growth factor receptor interacts with transcriptional intermediary factor 2 to activate cyclin D1 gene expression triggered by the oncoprotein latent membrane protein 1 publication-title: Carcinogenesis doi: 10.1093/carcin/bgs171 – volume: 1455 start-page: 34 issue: 1 year: 2019 end-page: 58 ident: CR27 article-title: Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation publication-title: Ann N Y Acad Sci doi: 10.1111/nyas.14249 – volume: 20 start-page: 2209 issue: 3 year: 2019 end-page: 2218 ident: CR10 article-title: Comprehensive analysis of expression profiles of long non–coding RNAs with associated ceRNA network involved in gastric cancer progression publication-title: Mol Med Rep – ident: CR36 – volume: 21 start-page: 351 issue: 1 year: 2021 ident: CR33 article-title: The prognostic outcome of ‘type 2 Diabetes Mellitus and Breast cancer’ association pivots on hypoxia-hyperglycemia axis publication-title: Cancer Cell Int doi: 10.1186/s12935-021-02040-5 – volume: 125 start-page: 104754 year: 2022 ident: CR42 article-title: Phorbol 12-myristate 13-acetate stimulation under hypoxia induces nuclear swelling with DNA outflow but not extracellular trap formation of neutrophils publication-title: Exp Mol Pathol doi: 10.1016/j.yexmp.2022.104754 – volume: 581 start-page: 2131 issue: 11 year: 2007 ident: 4548_CR7 publication-title: FEBS Lett doi: 10.1016/j.febslet.2007.02.066 – volume: 265 start-page: 137 issue: 2 year: 2015 ident: 4548_CR12 publication-title: Eur Arch Psychiatry Clin NeuroSci doi: 10.1007/s00406-014-0550-4 – volume: 13 start-page: 171 issue: 3 year: 2013 ident: 4548_CR9 publication-title: Cancer Biomark doi: 10.3233/CBM-130336 – volume: 9 start-page: 490 issue: 5 year: 2018 ident: 4548_CR19 publication-title: Cell Death Dis doi: 10.1038/s41419-018-0542-9 – volume: 1631 start-page: 157 year: 2016 ident: 4548_CR34 publication-title: Brain Res doi: 10.1016/j.brainres.2015.11.041 – volume: 7 start-page: 318 issue: 4 year: 2019 ident: 4548_CR24 publication-title: Immun Inflamm Dis doi: 10.1002/iid3.276 – volume: 1455 start-page: 34 issue: 1 year: 2019 ident: 4548_CR27 publication-title: Ann N Y Acad Sci doi: 10.1111/nyas.14249 – volume: 2 start-page: 494 issue: 9 year: 2006 ident: 4548_CR1 publication-title: Nat Clin Pract Neurol doi: 10.1038/ncpneuro0289 – volume: 364 start-page: 656 issue: 7 year: 2011 ident: 4548_CR41 publication-title: N Engl J Med doi: 10.1056/NEJMra0910283 – ident: 4548_CR15 doi: 10.3390/biomedicines8070191 – volume: 44 start-page: 1151 issue: 5 year: 2021 ident: 4548_CR40 publication-title: Cell Oncol (Dordr) doi: 10.1007/s13402-021-00625-w – volume: 9 start-page: 592 issue: 6 year: 2010 ident: 4548_CR13 publication-title: Genes Brain Behav doi: 10.1111/j.1601-183X.2010.00590.x – volume: 33 start-page: 1468 issue: 8 year: 2012 ident: 4548_CR16 publication-title: Carcinogenesis doi: 10.1093/carcin/bgs171 – volume: 131 start-page: 803 issue: 6 year: 2016 ident: 4548_CR3 publication-title: Acta Neuropathol doi: 10.1007/s00401-016-1545-1 – volume: 34 start-page: 6079 issue: 50 year: 2015 ident: 4548_CR17 publication-title: Oncogene doi: 10.1038/onc.2015.53 – volume: 53 start-page: 316 year: 2019 ident: 4548_CR29 publication-title: Cell Signal doi: 10.1016/j.cellsig.2018.10.020 – volume: 125 start-page: 104754 year: 2022 ident: 4548_CR42 publication-title: Exp Mol Pathol doi: 10.1016/j.yexmp.2022.104754 – volume: 11 start-page: 1955 year: 2020 ident: 4548_CR28 publication-title: Front Immunol doi: 10.3389/fimmu.2020.01955 – volume: 126 start-page: 1175 issue: 6 year: 2006 ident: 4548_CR8 publication-title: Cell doi: 10.1016/j.cell.2006.08.030 – volume: 46 start-page: 65 issue: 1 year: 2023 ident: 4548_CR31 publication-title: Cell Oncol (Dordr) doi: 10.1007/s13402-022-00734-0 – ident: 4548_CR36 doi: 10.1242/bio.038851 – volume: 152 start-page: 315 year: 2018 ident: 4548_CR26 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2018.04.009 – volume: 22 start-page: 1701 issue: 7 year: 2005 ident: 4548_CR14 publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.2005.04349.x – volume: 44 start-page: 1167 issue: 5 year: 2021 ident: 4548_CR39 publication-title: Cell Oncol (Dordr) doi: 10.1007/s13402-021-00629-6 – volume: 23 start-page: 20 issue: 2 year: 2021 ident: 4548_CR21 publication-title: Curr Oncol Rep doi: 10.1007/s11912-020-01006-6 – volume: 54 start-page: 6133 issue: 8 year: 2017 ident: 4548_CR35 publication-title: Mol Neurobiol doi: 10.1007/s12035-016-0156-0 – ident: 4548_CR2 doi: 10.15586/codon.glioblastoma.2017.ch16 – volume: 37 start-page: 411 issue: 3 year: 2016 ident: 4548_CR30 publication-title: Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol doi: 10.1007/s10072-015-2419-3 – volume: 92 start-page: 296 issue: 3 year: 2012 ident: 4548_CR37 publication-title: Exp Mol Pathol doi: 10.1016/j.yexmp.2012.03.004 – volume: 22 start-page: 223 issue: 1 year: 2022 ident: 4548_CR38 publication-title: Cancer Cell Int doi: 10.1186/s12935-022-02636-5 – volume: 70 start-page: 299 issue: 4 year: 2020 ident: 4548_CR6 publication-title: Cancer J Clin doi: 10.3322/caac.21613 – volume: 38 start-page: 19 issue: 1 year: 2017 ident: 4548_CR20 publication-title: Biomed Res (Tokyo Japan) doi: 10.2220/biomedres.38.19 – volume: 19 start-page: 3402 issue: 17 year: 2010 ident: 4548_CR23 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddq252 – volume: 20 start-page: 2209 issue: 3 year: 2019 ident: 4548_CR10 publication-title: Mol Med Rep – volume: 17 start-page: 3909 issue: 4 year: 2020 ident: 4548_CR11 publication-title: Math Biosci Engineering: MBE doi: 10.3934/mbe.2020217 – volume: 21 start-page: 351 issue: 1 year: 2021 ident: 4548_CR33 publication-title: Cancer Cell Int doi: 10.1186/s12935-021-02040-5 – volume: 131 start-page: 173 issue: 1 year: 2012 ident: 4548_CR5 publication-title: Int J Cancer doi: 10.1002/ijc.26335 – volume: 78 start-page: 3484 issue: 13 year: 2018 ident: 4548_CR18 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-17-3454 – volume: 24 start-page: 1489 issue: 10 year: 2019 ident: 4548_CR25 publication-title: Mol Psychiatry doi: 10.1038/s41380-017-0011-3 – volume: 21 start-page: v1 issue: Suppl 5 year: 2019 ident: 4548_CR4 publication-title: Neuro Oncol doi: 10.1093/neuonc/noz150 – volume: 14 start-page: 284 issue: 2 year: 2017 ident: 4548_CR22 publication-title: Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics doi: 10.1007/s13311-017-0519-x – volume: 19 start-page: 1435 issue: 11 year: 2017 ident: 4548_CR32 publication-title: Neuro Oncol doi: 10.1093/neuonc/nox081 |
| SSID | ssj0004731 |
| Score | 2.41235 |
| Snippet | Background
Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but... Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical... BackgroundGlioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 63 |
| SubjectTerms | Cell proliferation Central nervous system Genomes Glioma Glioma cells Hypoxia Malignancy Medical prognosis Medicine Medicine & Public Health Molecular modelling Neurology Oncology Prognosis Transcriptomes Tumor suppression Tumor suppressor genes Tumorigenesis |
| SummonAdditionalLinks | – databaseName: Proquest Health & Medical Complete dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED90gvgifludEsE3Da5t-rEnkeEY4sQHB30rSZvIYGvn2vn3e2nTFRn6FghN00t6-f3uLncAtynXlawcn3q2DClL0oDyBPeySLjtO0y4YeWKGb_5owl7ibzIGNwKE1bZ6MRKUad5om3kD67GKrZGC4-LL6qrRmnvqimhsQ07OnWZJl9BFLT3IgNTjxCVgddnkbk0U1-dQy7Uo3hiUZ2EDqf5-2DaQJsbntLqABoewL5BjuSpXupD2JLZEeyOjW_8GIaD99fIIdOCcJLl33JGytU8X5JitaiCXbHJs5RMKyuCLAgiP6Kjs7K8wGemGfmcTfM5P4HJ8PljMKKmSgJNEHqVVDnKlx5zbKV8nylkKNgSXCFQSfATeaL6qA1ZIG1PSaF0NSqR6F7pIJVLhXsKnSzP5DmQELkF0rGQ91PkXUqEruh70pMiFVKn3bfgrhFRvKiTYcRt2mMt0BgFGlcCjZkF3UaKsfkxirhdRgtu1t24pbWfgmcyXxUxIhCGZLnnBhac1dJfv84NsQt5tQX3zXK0g_89l4v_53IJew6ClTq2rAudcrmSVwg2SnFd7agff9XNNg priority: 102 providerName: ProQuest |
| Title | CPLX2 is a novel tumor suppressor and improves the prognosis in glioma |
| URI | https://link.springer.com/article/10.1007/s11060-023-04548-4 https://www.ncbi.nlm.nih.gov/pubmed/38427133 https://www.proquest.com/docview/3013915226 https://www.proquest.com/docview/2934274037 |
| Volume | 167 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS8MwFD7oBuKLeLc6RwTftLC26e1xG5tD3RjioD6VpE1ksLVjXf39nnTthkwffGkCadP25DT5vp5LAO5jpnayMh3dNoSn0yh2dRahLvOIGY5JueUVppjhyBlM6HNgB2VQWFZ5u1cmyWKm3ga7IXtp6bjG6CptHHa8D3UbubvS64nZ3kZDuuUuhDgF2D4NylCZ3_v4uRztYMwd-2ix7PSP4ajEi6S9HuAT2BPJKRwMS4v4GfS749fAJNOMMJKkX2JGVvk8XZIsXxQurlhlSUymxb8DkRHEe0T5ZCVphtdME_I5m6Zzdg6Tfu-9O9DLvRH0CAHXSpemdIRNTUNKx6ESeQnWOJMITyJ8RRZJH-dA6grDloJLtQcVj1SrMJHAxdy6gFqSJuIKiIeMAkmYx_wY2ZbknsV9W9iCx1yoZPsaPFQiChfrFBjhNtmxEmiIAg0LgYZUg0YlxbD8HLLQUkDTUFBPg7tNMyqysk6wRKR5FiLuoEiRW5arweVa-pvbWR42IZvW4LEajm3nfz_L9f9Ov4FDVCe69jBrQG21zMUtQo4Vb8K-G7h49LpGE-rtfqczUuXTx0sPy05vNH5rFlr4DUBv0IE |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT-MwEB7xkIDLiscCWV5GghNr0TjOoweEUKEq0CIOIPXmtRMbVSpJl7SL-FP8RsZ5UCG03LhZsuJY4_H4-zzjGYCDRNpKViygvqsjyuMkpDJGXVaxdAPGlRcVrpjeTdC551d9vz8Dr_VbGBtWWdvEwlAnWWzvyI89i1VcixZOR3-prRplvat1CY1SLa71yzNStvzk8hzX95Cx9sVdq0OrqgI0RqgypoaZQPucucYEATeI6LGlpMGDPW4EDRmbJloPHmrXN1oZW71JxbZXM6Q-ifJw3FmY554X2lz9UWsaUsLDqv4hGh-_yfvVI53yqR5yrwbFE5LapHcolo8H4Sd0-8kzWxx47WX4USFVclaq1grM6HQVFnqVL34N2q3bbp-RQU4kSbN_ekjGk8fsieSTURFci02ZJmRQ3FronCDSJDYaLM1y_GaQkofhIHuUP-H-W-S3DnNplupNIBFyGaR_kWwmyPOMijzV9LWvVaK0TfPvwFEtIjEqk2-IaZplK1CBAhWFQAV3YLuWoqg2Yi6mauPA_ns3biHrF5Gpzia5QMTDkZw3vNCBjVL677_zIuxCHu_A73o5poP_fy6_vp7LHix27npd0b28ud6CJYZAqYxr24a58dNE7yDQGavdQrsI_PludX4DBqAKeg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ZS8QwEB48QHwRb-sZQZ80uE3TYx9ERF288UGhbzFpE1nQdrW7in_NX-ekh4uIvvkWCE3DZDLzTeYC2Eql7WTFAuq7OqI8SUMqE-RllUg3YFx5UemKuboOTu_4eezHI_DR5MLYsMpGJpaCOs0T-0a-51ms4lq0sGfqsIib485B75naDlLW09q006hY5EK_v6H5VuyfHeNZbzPWObk9OqV1hwGaIGzpU8NMoH3OXGOCgBtE9zhS0qCST1pBSyamjZKEh9r1jVbGdnJSiZ3VDM2gVHm47iiMhx6qTbxLYRwOczLDuhciCiK_zeM6YadK20M7rEVRW1JbAA9J9F0p_kC6P7y0pfLrTMNUjVrJYcVmMzCis1mYuKr98nPQObq5jBnpFkSSLH_Vj6Q_eMpfSDHolYG2OJRZSrrlC4YuCKJOYiPDsrzAb7oZeXjs5k9yHu7-hX4LMJblmV4CEqFdg6ZgJNsp2nxGRZ5q-9rXKlXalvx3YKchkehVhTjEsOSyJahAgoqSoII7sNpQUdSXshBDFnJg82sar5P1kchM54NCIPrhaKi3vNCBxYr6X7_zIpxCm96B3eY4hov_vpflv_eyARPIyOLy7PpiBSYZYqYqxG0VxvovA72GmKev1kvmInD_39z8CboxDtw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CPLX2+is+a+novel+tumor+suppressor+and+improves+the+prognosis+in+glioma&rft.jtitle=Journal+of+neuro-oncology&rft.au=Chen%2C+Yuanbing&rft.au=Ning%2C+Jieling&rft.au=Shu%2C+Long&rft.au=Wen%2C+Lingzhi&rft.date=2024-03-01&rft.issn=1573-7373&rft.eissn=1573-7373&rft.volume=167&rft.issue=1&rft.spage=63&rft_id=info:doi/10.1007%2Fs11060-023-04548-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-594X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-594X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-594X&client=summon |